Emergent BioSolutions to Report First Quarter 2025 Financial Results on May 7, 2025
Emergent BioSolutions (NYSE: EBS) has scheduled its first quarter 2025 financial results conference call for May 7, 2025, at 5:00 pm eastern time.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Emergent BioSolutions (NYSE: EBS) has scheduled its first quarter 2025 financial results conference call for May 7, 2025, at 5:00 pm eastern time. The company will provide investors and stakeholders access to the conference call through multiple channels:
- Live webcast access
- Telephone participation (requires advance registration)
- Replay availability on the company's Investors webpage
Registered telephone participants will receive confirmation emails with dial-in details, including a unique passcode and registrant ID for call access.
Details
News Market Reaction – EBS
The recorded move for EBS in the trading session of this news was +3.96%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
GAITHERSBURG, Md., April 22, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, May 7, 2025, at 5:00 pm eastern time to discuss the financial results for the first quarter of 2025.
Participants can access the conference call live via webcast, and also by visiting the Investors page of Emergent’s website. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call.
A replay of the call can be accessed from the Investors page of Emergent’s website.
About Emergent BioSolutions
At Emergent, our mission is to protect and save lives. For over 25 years, we’ve been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies. To learn more about how we help prepare communities around the world for today’s health challenges and tomorrow’s threats, visit our website and follow us on LinkedIn, X, Instagram, Apple Podcasts and Spotify.
Investor Contact:
Richard S. Lindahl
Executive Vice President, CFO
lindahlr@ebsi.com
Media Contact:
Assal Hellmer
Vice President, Communications
mediarelations@ebsi.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.